Oman: Doctors at Khoula Hospital reattach severed hand in complex surgery
The 14-hour operation was led by Dr Ahmed bin Mohammed al Wahaibi, Consultant Orthopaedic Surgeon and Head of the Hand and Microsurgery Department at Khoula Hospital. The procedure is considered a significant step in advanced microsurgery in Oman.
Dr Wahaibi said the success of the surgery was due to two key factors: the immediate first aid given at the site of the incident and the correct preservation of the severed hand and fingers according to international medical standards. 'Swift and safe transfer of the patient to Khoula Hospital's replantation centre was critical to restoring sensory and motor function,' he said.
The team carried out bone fixation, reconnected small blood vessels, removed damaged tissue, and sutured ligaments and arteries under a microscope. 'Such operations demand high precision and advanced techniques, showing the progress of Omani medical expertise,' Dr Wahaibi added.
After surgery, the patient's condition stabilised without complications such as infection or clotting. Early signs indicate promising recovery of sensation and movement, and the patient was discharged soon after the procedure.
Dr Wahaibi emphasised the importance of workplace safety, urging workers to follow safety measures, wear protective gear and ensure machinery is switched off during maintenance.
He also highlighted the need for quick response in trauma cases. 'Proper first aid, correct handling of the amputated part and fast transfer to a specialist centre can be crucial for successful treatment and recovery,' he said.
© Apex Press and Publishing Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Burjeel Medical City performs UAE's youngest infant liver transplant
Abu Dhabi: Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, has successfully performed the UAE's youngest infant liver transplant, saving the life of five-month-old Baby Ahmed Yahya, who was diagnosed with an ultra-rare genetic disorder. This milestone surgery was made possible through the living liver donation of his aunt and the expertise of a highly skilled multidisciplinary team. A Second Chance After Heartbreak For parents Yahya and Zainab Al Yassi, this year's World Organ Donation Day carries profound personal meaning. Baby Ahmed, their fifth child, is the couple's first surviving boy after the loss of another son, also named Ahmed in honor of his grandfather, to liver disease in 2010. When the newborn's liver enzyme levels rose shortly after birth, doctors diagnosed him with ATP6AP1-related congenital disorder of glycosylation, a genetic condition with fewer than 25 known cases worldwide. 'This disease is a severe, multisystem condition that particularly affects the liver. In Ahmed's case, the disorder was progressing rapidly toward liver failure. Given the rarity of the condition, there were no clear answers, only tough questions. Yet we had to act,' said Dr. Johns Shaji Mathew, Abdominal Transplant and Hepato-Pancreatico-Biliary Surgeon at BMC. Due to his critical condition, an urgent liver transplant became the only option. To avoid delays, the family sought a living donor. Ms. Haifaa, Ahmed's aunt and the wife of his father's brother, stepped forward and was found to be a perfect match. 'I still remember the pain when we lost our first son to liver disease. When we heard our second son had a similar problem, I thought this was our destiny. But the doctors at BMC gave us new hope. And my sister-in-law gave us life again,' said Yahya. 'I read everything I could find about organ donation. I realized that donating part of my liver could save his life, and I knew I had to do it. It is a bond that nothing in this world can break,' said Ahmed's aunt. A Complex Procedure The transplant took place on April 4, 2025. Led by Dr. Gourab Sen, Director – Transplant Surgery, Burjeel Abdominal Multi-Organ Transplant Program, and Dr. Johns Shaji Mathew, the surgical team prepared a mono-segment graft from the donor's liver to fit the infant's small abdominal cavity. Pediatric anesthesia was managed by Dr. Ramamurthy Baskaran, Division Chair of Anesthesia, along with Dr. George Jacob and Dr. Anshu S. Postoperative care was led by Dr. Kesava Ramakrishnan, Consultant, Pediatric Intensive Care Unit, and his team. 'This was a precision operation that lasted 12 hours, including the donor and the recipient surgery. We used a mono-segment graft, a tiny part of the donor's liver, shaped exactly to fit the baby's anatomy. In an infant this small, every structure is delicate beyond imagination, each vessel was thinner than a matchstick, and the margin for error was virtually zero,' said Dr. Gourab. Following the operation, Ahmed was extubated soon, began feeding within days, and showed excellent liver function. Pediatric intensivists, gastroenterologists, dietitians, radiologists, and rehabilitation specialists supported his recovery. He will continue to receive specialized nutritional support, immune monitoring, and family counseling under BMC's long-term care program. 'My baby's recovery is nothing short of a miracle. We were once a family living in fear of losing another child, but today, we are celebrating a second chance at life. I hope our story inspires others to come forward, to learn more, and to consider becoming donors. You never know whose life you might change,' said Yahya. The HAYAT National Program invites the public to learn more about related living organ donation, where a healthy person donates to a family member in need. This life-saving act can shorten waiting times and transform lives. Speak with your healthcare provider and discover how you can give the gift of life. For more information on how to register as an organ donor, visit: Hayat Organ Donation Program | Ministry of Health and Prevention… (
Zawya
2 days ago
- Zawya
Oman to produce medical diagnostic machines locally
A strategic Memorandum of Understanding (MoU) was signed by Dr Mohammad Mahmoodi, CEO of Carbon Technologies, and Dr Frank Vitzthum, Board Member and CTO of R-Biopharm, Germany, in the presence of Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation, on Tuesday. Under the MoU, advanced diagnostic manufacturing will be localised in Oman, supporting technology transfer and enhancing the country's health innovation ecosystem. The partnership will enable integration of state-of-the-art assay technologies into its local production lines, supporting both national and regional healthcare priorities. 'It is a milestone MoU in Oman's journey towards eliminating tuberculosis and other diseases from the country, and both communicable diseases and NCDs,' said Dr Rahma bint Ibrahim al Mahrouqiyah, Minister of Higher Education, Research and Innovation. 'I'm optimistic and this will pave the way for various scientific advancements in the country, especially when it is located near SQU and within the Innovation Park Muscat. We have begun, and we look forward to having an international consortium to eradicate both communicable and non-communicable diseases. We look forward to collaborating with regional, national and international partners so that we can cooperate with the leading players,' she added. Speaking to the Observer, Dr Mohammad Mahmoudi, Chief Executive Officer of Carbon Technologies, said that this collaboration is a testament to Oman's growing capacity in innovation-driven industries and its strategic openness to global partnerships. 'Together with R-Biopharm, we aim to elevate diagnostic standards, nurture Omani talent and contribute to national healthcare resilience,' Dr Mohammad added. Aligned with the objectives of Oman Vision 2040, the MoU supports national goals in biotechnology, scientific research and industrial innovation. Speaking on the sidelines of the signing ceremony, Eng Said bin Nasser al Salmi, Board Member of Carbon Technologies, said that the MoU would open up more opportunities to leverage Carbon Technologies as a leading Omani company and expand local R&D capabilities to serve both domestic and international markets in the healthcare industry and position Oman among the leading innovation hubs in such sectors. Dr Dirk Dressler, Head of Business Development at R-Biopharm AG, said, 'We are honoured to partner with Oman's Carbon Technologies. This collaboration reflects our confidence in Oman's capabilities and our shared commitment to delivering high-quality, accessible diagnostics across the region." 2025 © All right reserved for Oman Establishment for Press, Publication and Advertising (OEPPA) Provided by SyndiGate Media Inc. (
Zawya
7 days ago
- Zawya
INTERVIEW: Strong Q2 results underscore strategy shift to complex care
Burjeel Holdings, the ADX-listed super-specialty healthcare provider, reported strong second-quarter results with net profit more than doubling and revenue rising nearly 19 percent year-on-year, driven by higher patient volumes and continued expansion in specialty services. In an interview with Zawya Projects, CEO John Sunil said the second quarter performance validated the group's strategy of investing in complex care areas such as oncology, women's health, and surgical specialties. 'The second quarter was strong for us, both in terms of results and execution,' Sunil said. 'We saw strong momentum in complex care, particularly in oncology, women's health, and surgical specialties.' The healthcare group has been expanding its regional footprint with new specialty centres in Dubai, Sharjah, Al Ain, and Oman, along with strategic acquisitions such as the Advanced Care Oncology Centre and a major rehabilitation facility in Riyadh. Despite deploying 403 million UAE dirhams in capital investments in the first half of 2025, Burjeel maintained a stable balance sheet and a 47 percent dividend payout, reflecting strong cash flows. The company reaffirmed its mid-teens revenue growth guidance for FY2025, with UAE and Saudi operations expected to anchor growth, while expansion into emerging markets like Africa will follow an asset-light Operations and Maintenance (O&M) model. Excerpts from the interview: What drove the strong Q2 performance and margin gains? We recorded 19 percent revenue growth and more than doubled our net profit, which was driven by operating leverage and better optimisation of our asset base. We have been very intentional about building a performance-driven culture. Even with 143 new physicians on boarded over the past year, we managed to optimise personnel costs through better workforce planning and scheduling. In fact, overheads came down by seven percent compared to the previous quarter and over 13 percent compared to Q4 last year. These improvements in cost control, combined with the top-line growth, led to a significant improvement in EBITDA margins. What's the strategy behind your mental health and rehab platforms? We believe in building a truly integrated model of care. With Alkalma, we are building a comprehensive mental health platform that has already launched four centres across the UAE and Saudi Arabia. Demand has been robust and continues to grow across different age groups. Similarly, our PhysioTherabia network in Saudi Arabia has grown to over 30 centres, supported by long-term government contracts. These platforms allow us to offer preventive, supportive, and recovery-oriented services that reduce the burden on acute care systems and improve overall outcomes. With the AED 170 million acquisition of Medeor Hospital's Dubai building, how does asset ownership support Burjeel's long-term strategic and financial goals? Owning the Medeor Hospital building in Dubai was a strategic move. It eliminated a long-term lease, gave us full operational control, and converted a high-performing facility into a capital asset. That translates directly into financial flexibility and cost efficiency. This investment also reflects our long-term commitment to Dubai as a strategic market. Could you share insights into your capital allocation strategy? Our capital allocation is guided by impact and long-term value. We're not just adding facilities - we're scaling services that meet clear clinical needs and deliver returns. Whether expanding oncology care, launching the Trust Fertility platform, or extending access to primary care, each investment aligns with our core strategy. At the same time, we are maintaining financial discipline. Free cash flow conversion improved significantly, and our debt remains well within manageable levels. We are focused on ensuring that each new asset is launched efficiently and begins contributing at its full potential. Expansion is important, but we are equally focused on execution and cost discipline. What are your expectations for the rest of FY2025? We are optimistic about the rest of the year. Many of our newly launched assets are starting to scale up. As utilisation improves, we expect continued margin improvement. We continue to target mid-teens revenue growth for the full year, supported by ongoing expansion in the UAE and Saudi Arabia. Our priorities remain clear on enhancing efficiency, deepening our subspecialty platforms, and scaling services through our core network and partnerships - particularly in high-impact areas such as oncology, transplant, fertility, orthopedics, and neuroscience. It is important to remember that major investments in specialised care and technology take time to translate into full financial returns. But this quarter shows that our strategy is beginning to deliver real value. How do you balance shareholder returns with reinvestment needs? We are committed to delivering value to our shareholders while ensuring the business is well-positioned for long-term growth. The 47 percent payout ratio reflects that balance. It rewards shareholders and preserves the flexibility we need to keep investing in our platform. As we continue to scale, we are open to exploring alternative funding instruments such as Sukuk, provided they align with our financial and strategic goals. But we will remain measured in our approach and focused on ensuring any capital raised is used for initiatives that create sustainable value. With rising rates, pricing pressures, and tighter regulation across MENA, how is Burjeel navigating this challenging operating environment? We are navigating this environment by staying agile and focusing on efficiency. Our diverse portfolio, which includes facilities across the UAE, Saudi Arabia, and Oman, and our mix of public and private contracts, provides us with a degree of resilience. We are also making meaningful progress in digital transformation. With tools like Oracle EMR and AI-based diagnostics, we are gaining better visibility across the system and improving both clinical and operational performance. This helps us manage costs and also positions us well for outcome-based reimbursement models, which are becoming more important in this regulatory landscape. Amid macro headwinds and expansion, how confident are you in meeting your FY2025 growth target? Yes, we are confident in our growth target. The strong performance in the first half gives us a solid platform. With many new centres coming online and strong demand for complex care, we expect momentum to continue into the second half. The UAE remains our largest and most mature market, particularly in high-acuity specialties. A great example is Trust Fertility Centre, now the largest of its kind in the country. It broke even within six months, treated over 1,800 patients, and delivered outcomes above global benchmarks. This type of replicable, high-impact model supports both our growth ambitions and our commitment to clinical excellence. Saudi Arabia continues to be a key growth engine. We are scaling our PhysioTherabia network and preparing to launch day surgery platforms. In emerging markets like Africa, we are exploring opportunities strictly through asset-light, zero-capex Operations and Management (O&M) partnerships. This allows us to expand our presence efficiently, without balance sheet exposure, while capturing growth opportunities across the regions. (Reporting by SA Kader; Editing by Anoop Menon) (
